CHINA NATIONAL ACCORD MEDICINES CORPORATION LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.11 CNY | -2.42% |
|
-0.31% | +21.11% |
| Sales 2024 * | 80.71B 11.14B 15.23B | Sales 2025 * | 85.88B 11.85B 16.2B | Capitalization | 18B 2.48B 3.4B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.78B 245M 335M | Net income 2025 * | 1.89B 261M 357M | EV / Sales 2024 * | 0.25 x |
| Net Debt 2024 * | 2.48B 342M 468M | Net Debt 2025 * | 3.35B 463M 632M | EV / Sales 2025 * | 0.25 x |
| P/E ratio 2024 * |
11
x | P/E ratio 2025 * |
10.3
x | Employees | 39,449 |
| Yield 2024 * |
2.16% | Yield 2025 * |
2.35% | Free-Float | 42.7% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.42% | ||
| 1 week | -0.31% | ||
| Current month | +14.29% | ||
| 1 month | +17.74% | ||
| 3 months | +16.84% | ||
| 6 months | +24.02% | ||
| Current year | +21.11% |
1 week
33.80
36.60
1 month
29.8136.60
Current year
26.0636.60
1 year
26.0652.55
3 years
20.3852.55
5 years
20.3852.55
10 years
20.3872.39
| Managers | Title | Age | Since |
|---|---|---|---|
Zhao Xiong Lin
CEO | Chief Executive Officer | 57 | 08-11-30 |
Guo Lin Gu
DFI | Director of Finance/CFO | 49 | 20-05-27 |
Min Lin
CHM | Chairman | 59 | 08-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhao Xiong Lin
CEO | Chief Executive Officer | 57 | 08-11-30 |
Min Lin
CHM | Chairman | 59 | 08-11-30 |
Yi Jian Wu
BRD | Director/Board Member | 54 | 20-11-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 35.11 | -2.42% | 6,372,578 |
| 24-04-25 | 35.98 | +2.95% | 6,057,706 |
| 24-04-24 | 34.95 | +2.52% | 6,009,046 |
| 24-04-23 | 34.09 | -4.59% | 7,990,845 |
| 24-04-22 | 35.73 | +1.45% | 7,113,052 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
China National Accord Medicines Corporation Ltd. is a China-based company principally engaged in the pharmaceutical wholesaling, retailing and manufacturing businesses. The Company's main products include antibiotic preparations, power injections, antibiotic Active Pharmaceutical Ingredients (APIs), respiratory system drugs and cardiovascular and cerebrovascular system drugs, among others. The Company is also involved in the provision of logistics and storage services, leasing services and training services, among others. The Company distributes its products mainly in domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
35.11
CNY
Average target price
37.97
CNY
Spread / Average Target
+8.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.11% | 2.48B | |
| +17.35% | 71.39B | |
| +5.38% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| +0.49% | 4.54B | |
| +17.12% | 4.31B | |
| -3.38% | 3.93B | |
| -2.61% | 3.86B | |
| +22.08% | 3.64B |
- Stock Market
- Equities
- 000028 Stock
